Status: current, Sufficiently defined by necessary conditions definition status (core metadata concept). Date: 31-Jul 2018. Module: SNOMED CT core
Descriptions:
| Id | Description | Lang | Type | Status | Case? | Module |
| 3693356010 | Product containing precisely heparinoid 2 milligram/1 gram and salicylic acid 20 milligram/1 gram conventional release cutaneous gel (clinical drug) | en | Fully specified name | Active | Entire term case insensitive (core metadata concept) | SNOMED CT core |
| 3693357018 | Heparinoid 2 mg/g and salicylic acid 20 mg/g cutaneous gel | en | Synonym (core metadata concept) | Active | Entire term case insensitive (core metadata concept) | SNOMED CT core |
| 3550811000005119 | heparinoid + salicylsyre 0,2 %/2 % gel | da | Synonym (core metadata concept) | Active | Entire term case insensitive (core metadata concept) | Danish module (core metadata concept) |
| Outbound Relationships | Type | Target | Active | Characteristic | Refinability | Group | Values |
| Product containing precisely heparinoid 2 milligram/1 gram and salicylic acid 20 milligram/1 gram conventional release cutaneous gel (clinical drug) | Is a | Salicylic acid product | false | Inferred relationship | Some | ||
| Product containing precisely heparinoid 2 milligram/1 gram and salicylic acid 20 milligram/1 gram conventional release cutaneous gel (clinical drug) | Is a | salicylsyre gel | false | Inferred relationship | Some | ||
| Product containing precisely heparinoid 2 milligram/1 gram and salicylic acid 20 milligram/1 gram conventional release cutaneous gel (clinical drug) | The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. | keratolytisk middel | false | Inferred relationship | Some | ||
| Product containing precisely heparinoid 2 milligram/1 gram and salicylic acid 20 milligram/1 gram conventional release cutaneous gel (clinical drug) | The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. | Salicylic acid (substance) | false | Inferred relationship | Some | ||
| Product containing precisely heparinoid 2 milligram/1 gram and salicylic acid 20 milligram/1 gram conventional release cutaneous gel (clinical drug) | Is a | Product containing heparinoid (medicinal product) | false | Inferred relationship | Some | ||
| Product containing precisely heparinoid 2 milligram/1 gram and salicylic acid 20 milligram/1 gram conventional release cutaneous gel (clinical drug) | Is a | Product containing salicylic acid (medicinal product) | false | Inferred relationship | Some | ||
| Product containing precisely heparinoid 2 milligram/1 gram and salicylic acid 20 milligram/1 gram conventional release cutaneous gel (clinical drug) | The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. | Heparinoid (substance) | false | Inferred relationship | Some | ||
| Product containing precisely heparinoid 2 milligram/1 gram and salicylic acid 20 milligram/1 gram conventional release cutaneous gel (clinical drug) | The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. | middel til topikal anvendelse | false | Inferred relationship | Some | ||
| Product containing precisely heparinoid 2 milligram/1 gram and salicylic acid 20 milligram/1 gram conventional release cutaneous gel (clinical drug) | Has manufactured dose form | kutan OG/ELLER transdermal doseringsform | false | Inferred relationship | Some | ||
| Product containing precisely heparinoid 2 milligram/1 gram and salicylic acid 20 milligram/1 gram conventional release cutaneous gel (clinical drug) | Has manufactured dose form | A semi-solid dose form consisting of a hydrophilic gel. | false | Inferred relationship | Some | ||
| Product containing precisely heparinoid 2 milligram/1 gram and salicylic acid 20 milligram/1 gram conventional release cutaneous gel (clinical drug) | Is a | Product containing salicylic acid in topical dosage form | false | Inferred relationship | Some | ||
| Product containing precisely heparinoid 2 milligram/1 gram and salicylic acid 20 milligram/1 gram conventional release cutaneous gel (clinical drug) | Has manufactured dose form | Cutaneous gel | true | Inferred relationship | Some | ||
| Product containing precisely heparinoid 2 milligram/1 gram and salicylic acid 20 milligram/1 gram conventional release cutaneous gel (clinical drug) | This attribute specifies the numerator unit for the concentration strength of a product. | mg | true | Inferred relationship | Some | 2 | |
| Product containing precisely heparinoid 2 milligram/1 gram and salicylic acid 20 milligram/1 gram conventional release cutaneous gel (clinical drug) | Count of base of active ingredient | to | false | Inferred relationship | Some | ||
| Product containing precisely heparinoid 2 milligram/1 gram and salicylic acid 20 milligram/1 gram conventional release cutaneous gel (clinical drug) | This attribute specifies the denominator unit for the concentration strength of a product. | g | true | Inferred relationship | Some | 1 | |
| Product containing precisely heparinoid 2 milligram/1 gram and salicylic acid 20 milligram/1 gram conventional release cutaneous gel (clinical drug) | The most specific description of a substance present in the manufactured dose form, before any dilution or transformation. It includes modifiers, such as salts, esters, polymers (e.g. pegylation), and/or solvates (including waters of hydration). | Heparinoid (substance) | false | Inferred relationship | Some | 2 | |
| Product containing precisely heparinoid 2 milligram/1 gram and salicylic acid 20 milligram/1 gram conventional release cutaneous gel (clinical drug) | This attribute represents an ingredient that is the part of the active ingredient that the strength of a given product is based upon. | Heparinoid (substance) | false | Inferred relationship | Some | 2 | |
| Product containing precisely heparinoid 2 milligram/1 gram and salicylic acid 20 milligram/1 gram conventional release cutaneous gel (clinical drug) | This attribute specifies the denominator unit for the concentration strength of a product. | g | true | Inferred relationship | Some | 2 | |
| Product containing precisely heparinoid 2 milligram/1 gram and salicylic acid 20 milligram/1 gram conventional release cutaneous gel (clinical drug) | This attribute specifies the numerator unit for the concentration strength of a product. | mg | true | Inferred relationship | Some | 1 | |
| Product containing precisely heparinoid 2 milligram/1 gram and salicylic acid 20 milligram/1 gram conventional release cutaneous gel (clinical drug) | Has concentration strength numerator value | to | false | Inferred relationship | Some | 2 | |
| Product containing precisely heparinoid 2 milligram/1 gram and salicylic acid 20 milligram/1 gram conventional release cutaneous gel (clinical drug) | The most specific description of a substance present in the manufactured dose form, before any dilution or transformation. It includes modifiers, such as salts, esters, polymers (e.g. pegylation), and/or solvates (including waters of hydration). | Salicylic acid (substance) | false | Inferred relationship | Some | 1 | |
| Product containing precisely heparinoid 2 milligram/1 gram and salicylic acid 20 milligram/1 gram conventional release cutaneous gel (clinical drug) | This attribute represents an ingredient that is the part of the active ingredient that the strength of a given product is based upon. | Salicylic acid (substance) | false | Inferred relationship | Some | 1 | |
| Product containing precisely heparinoid 2 milligram/1 gram and salicylic acid 20 milligram/1 gram conventional release cutaneous gel (clinical drug) | Has concentration strength denominator value | en | false | Inferred relationship | Some | 1 | |
| Product containing precisely heparinoid 2 milligram/1 gram and salicylic acid 20 milligram/1 gram conventional release cutaneous gel (clinical drug) | Has concentration strength denominator value | en | false | Inferred relationship | Some | 2 | |
| Product containing precisely heparinoid 2 milligram/1 gram and salicylic acid 20 milligram/1 gram conventional release cutaneous gel (clinical drug) | Has concentration strength numerator value | 20 | false | Inferred relationship | Some | 1 | |
| Product containing precisely heparinoid 2 milligram/1 gram and salicylic acid 20 milligram/1 gram conventional release cutaneous gel (clinical drug) | Is a | Heparinoid and salicylic acid only product in cutaneous dose form | true | Inferred relationship | Some | ||
| Product containing precisely heparinoid 2 milligram/1 gram and salicylic acid 20 milligram/1 gram conventional release cutaneous gel (clinical drug) | Plays role | Antifungal therapeutic role (role) | false | Inferred relationship | Some | ||
| Product containing precisely heparinoid 2 milligram/1 gram and salicylic acid 20 milligram/1 gram conventional release cutaneous gel (clinical drug) | The most specific description of a substance present in the manufactured dose form, before any dilution or transformation. It includes modifiers, such as salts, esters, polymers (e.g. pegylation), and/or solvates (including waters of hydration). | Heparinoid (substance) | true | Inferred relationship | Some | 1 | |
| Product containing precisely heparinoid 2 milligram/1 gram and salicylic acid 20 milligram/1 gram conventional release cutaneous gel (clinical drug) | This attribute represents an ingredient that is the part of the active ingredient that the strength of a given product is based upon. | Heparinoid (substance) | true | Inferred relationship | Some | 1 | |
| Product containing precisely heparinoid 2 milligram/1 gram and salicylic acid 20 milligram/1 gram conventional release cutaneous gel (clinical drug) | The most specific description of a substance present in the manufactured dose form, before any dilution or transformation. It includes modifiers, such as salts, esters, polymers (e.g. pegylation), and/or solvates (including waters of hydration). | Salicylic acid (substance) | true | Inferred relationship | Some | 2 | |
| Product containing precisely heparinoid 2 milligram/1 gram and salicylic acid 20 milligram/1 gram conventional release cutaneous gel (clinical drug) | This attribute represents an ingredient that is the part of the active ingredient that the strength of a given product is based upon. | Salicylic acid (substance) | true | Inferred relationship | Some | 2 | |
| Product containing precisely heparinoid 2 milligram/1 gram and salicylic acid 20 milligram/1 gram conventional release cutaneous gel (clinical drug) | Plays role | Antivaricose therapeutic role (role) | false | Inferred relationship | Some |
| Inbound Relationships | Type | Active | Source | Characteristic | Refinability | Group |
This concept is not in any reference sets
FHIR